Tissium
Tissium develops biomorphic programmable polymers designed to reconstruct damaged tissue and restore natural function across multiple clinical areas. The company's platform includes the COAPTIUM CONNECT system, an FDA-authorized sutureless nerve coaptation technology, and a pipeline targeting cardiovascular and gastrointestinal applications. These solutions are engineered for use in both open surgery and minimally invasive procedures.
Visit websiteParis, France
Healthtech
Medical Devices
Biotechnology
Funding summary
- Total raised
- €160.0M
- Funding rounds
- 4
Investors in Tissium
Investors on record for Tissium. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Tissium?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors